Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clotrimazole + neomycin + polymyxin B + tetracaine
- Development stage
- Unknown
- Lead developer
- Laboratorios Mallén
- Modality
- Small Molecules, Peptides
- Administration
- Otic
01
Overview
Otofar is a multi-ingredient otic solution developed and marketed by Laboratorios Mallén for the treatment of otitis externa and otitis media complicated by bacterial or fungal infections, pruritus, or pain. It is a fixed-dose combination containing four active ingredients: clotrimazole (an imidazole antifungal), neomycin (an aminoglycoside antibiotic), polymyxin B (a polypeptide antibiotic), and tetracaine (an ester-type local anesthetic). Clotrimazole inhibits fungal lanosterol 14-alpha demethylase to disrupt cell membrane synthesis, while neomycin and polymyxin B target bacterial protein synthesis and outer membrane integrity, respectively. Tetracaine blocks voltage-gated sodium channels to provide rapid local pain relief.
- Brand names
- Otofar
- Other names
- clotrimazol + neomicina + polimixina B + tetracaínaclotrimazol + neomicina + polimixina B sulfato + tetracaína clorhidratoclotrimazole + neomycin + polymyxin B + tetracaine hydrochloride
02
Targets
Bacterial RibosomeCYP51A1 (Sterol 14α-demethylase)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)
Beyond the preview
Go deeper on clotrimazole + neomycin + polymyxin B + tetracaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clotrimazole + neomycin + polymyxin B + tetracaine.